Envestnet Asset Management Inc Bio Line Rx Ltd. Transaction History

Envestnet Asset Management Inc

$302 Billion
Q3 2024

A detailed history of Envestnet Asset Management Inc transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Envestnet Asset Management Inc holds 239,186 shares of BLRX stock, worth $47,837. This represents 0.0% of its overall portfolio holdings.

Number of Shares

239,186

Previous 213,833 11.86%

Holding current value

$47,837

Previous $121,000 6.61%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 06, 2024	BUY	$0.53 - $0.87 $13,437 - $22,057	25,353 Added 11.86%	239,186 $129,000
Q2 2024 Aug 08, 2024	BUY	$0.56 - $0.86 $89,279 - $137,108	159,428 Added 293.04%	213,833 $121,000
Q1 2024 May 13, 2024	BUY	$1.03 - $1.56 $7,990 - $12,102	7,758 Added 16.63%	54,405 $60,000
Q4 2023 Feb 13, 2024	SELL	$1.31 - $1.86 $15,049 - $21,367	-11,488 Reduced 19.76%	46,647 $73,000
Q3 2023 Nov 13, 2023	SELL	$1.23 - $2.45 $12,656 - $25,210	-10,290 Reduced 15.04%	58,135 $105,000
Q2 2023 Aug 04, 2023	SELL	$0.96 - $1.78 $29,271 - $54,273	-30,491 Reduced 30.83%	68,425 $109,000
Q1 2023 May 11, 2023	BUY	$0.56 - $0.89 $55,392 - $88,035	98,916 New	98,916 $88,000
Q3 2022 Nov 10, 2022	SELL	$0.88 - $1.91 $18,929 - $41,086	-21,511 Reduced 41.89%	29,839 $28,000
Q2 2022 Aug 03, 2022	SELL	$1.06 - $1.82 $18,868 - $32,396	-17,800 Reduced 25.74%	51,350 $66,000
Q1 2022 May 04, 2022	SELL	$1.46 - $2.18 $77,488 - $115,701	-53,074 Reduced 43.42%	69,150 $118,000
Q4 2021 Feb 04, 2022	BUY	$1.98 - $3.06 $157,006 - $242,645	79,296 Added 184.72%	122,224 $249,000
Q3 2021 Oct 07, 2021	BUY	$2.65 - $3.35 $113,759 - $143,808	42,928 New	42,928 $118,000

Others Institutions Holding BLRX

# of Institutions

Shares Held

3.35M

Call Options Held

46.5K

Put Options Held

6.3K

View Full List

About BioLineRx Ltd.

Ticker BLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,524,500
Market Cap $12.3M
Description
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...

More about BLRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Envestnet Asset Management Inc with notifications on news.

Account

Envestnet Asset Management Inc Bio Line Rx Ltd. Transaction History